Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 5/20 | 0.35 |
| ▸ | ELANE | P08246 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | TTR | P02766 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | MMP14 | P50281 | 1/20 | 0.31 |
| ▸ | MMP17 | Q9ULZ9 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8661339 | 0.80 | ALDH1A1 (0.42) | ALDH1A1AKR1B1CYP2C19 | |
| SCHEMBL5935684 | 0.78 | ALDH1A1 (0.42) | ALDH1A1MMP2MMP3MMP9MMP13 | |
| SCHEMBL13103908 | 0.78 | ALDH1A1 (0.42) | ALDH1A1MMP2MMP3MMP9MMP13 | |
| SCHEMBL8660046 | 0.75 | ALDH1A1 (0.39) | ALDH1A1AKR1B1CYP2C19 | |
| SCHEMBL8660050 | 0.75 | ALDH1A1 (0.39) | ALDH1A1AKR1B1CYP2C19 | |
| SCHEMBL944078 | 0.72 | ALDH1A1 (0.57) | ALDH1A1MMP2MMP9MMP13TTR | |
| SCHEMBL941900 | 0.72 | ALDH1A1 (0.57) | ALDH1A1MMP2MMP9MMP13TTR | |
| SCHEMBL940446 | 0.72 | ALDH1A1 (0.57) | ALDH1A1MMP2MMP9MMP13TTR | |
| SCHEMBL943431 | 0.70 | PLA2G7 (0.45) | PLA2G7ALDH1A1ELANEATMMMP2 | |
| SCHEMBL940749 | 0.69 | PLA2G7 (0.33) | PLA2G7AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003853-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | US | disclosed |
| US-7754750-B2 | a -5 substituted 1-H,3-H-imidazolidine-2,4-dione such as 5-(2-{[4-(4'-fluoro[1,1'-biphenyl]-4-yl)-1-piperazinyl]sulfonyl}ethyl)-2,4-imidazolidinedione; protease inhibitors, especially metalloelastase (MMP12) | ASTRAZENECA AB (SE) | 2010-07-13 | — | — | US | disclosed |
| US-7625934-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2009-12-01 | — | — | US | disclosed |
| US-20080306065-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| US-7427631-B2 | especially as inhibitors of MMP12 | ASTRAZENECA AB (SE) | 2008-09-23 | — | — | US | disclosed |
| US-20080171882-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| EP-1370556-B1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-07-19 | — | — | EP | disclosed |
| EP-1676846-A2 | Hydantoin derivatives as MMP inhibitors | AstraZeneca AB (SE) | 2006-07-05 | — | — | EP | disclosed |
| US-20040147573-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003853-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | PLA2G7 289/4885ALDH1A1 612/4885AKR1B1 1872/4885 |
| US-20080306065-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | PLA2G7 289/4885ALDH1A1 612/4885AKR1B1 1872/4885 |
| US-20080171882-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | PLA2G7 289/4885ALDH1A1 612/4885AKR1B1 1872/4885 |
| US-20040147573-A1 | Metalloproteinase inhibitors | MMP12, MMP7, MMP10 | PLA2G7 776/4885ALDH1A1 1250/4885AKR1B1 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.